Form 4: ImmuCell Director Receives Stock Option Grant

Director Paul R. Wainman was granted 11,933 non-qualified stock options as compensation for board service.

Summary

• Director Paul R. Wainman received a grant of 11,933 non-qualified stock options on April 15, 2026.
• The options have an exercise price of $7.60 per share.
• The grant is part of the standard compensation package for members of the ImmuCell Corporation board of directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in minor potential dilution for existing shareholders upon future exercise of the options.

Risks

• Market price volatility may impact the future value of these options.

Future Outlook

The options vest in three annual installments starting April 15, 2027, and expire on April 15, 2036.

Management Comments

• The options were granted by the issuer to compensate directors for services on the Issuer's board of directors.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the biotechnology sector to ensure alignment between leadership and shareholders.

Comparison to Industry Standards

• The use of multi-year vesting schedules for director options is consistent with standard corporate governance practices for small-cap biotech firms.

Stakeholder Impact

• Shareholders: Minor dilution impact upon future exercise.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of 3,977 shares on April 15, 2027.
• Vesting of 3,977 shares on April 15, 2028.
• Vesting of 3,979 shares on April 15, 2029.

Key Dates

Keywords

ImmuCell, ICCC, Form 4, Director Compensation, Stock Options, Insider Transaction